Titlebook: Optimizing Breast Cancer Management; William J. Gradishar Book 2018 Springer International Publishing AG 2018 Anti - HER2 Therapy.Bisphosp

只看該作者 · 發(fā)表于 2025-3-23 15:32:32

Immune Checkpoint Blockade for Breast Cancer,rained cytotoxic T effector cell activity—it promotes peripheral T effector cell exhaustion and conversion of T effector cells to immunosuppressive T regulatory (Treg) cells. Immune checkpoint inhibitors, which block the PD-1/PD-L1 axis and reactivate cytotoxic T effector cell function, are actively

只看該作者 · 發(fā)表于 2025-3-23 22:01:09

只看該作者 · 發(fā)表于 2025-3-23 22:11:10

978-3-319-88901-6Springer International Publishing AG 2018

只看該作者 · 發(fā)表于 2025-3-24 06:00:18

只看該作者 · 發(fā)表于 2025-3-24 10:02:59

William J. GradisharFocuses on recent data that influence surgical techniques, radiation therapy techniques, and medical therapeutics.Discusses new insights into genetic and lifestyle risks for breast cancer and risk red

只看該作者 · 發(fā)表于 2025-3-24 11:23:32

Cancer Treatment and Researchhttp://image.papertrans.cn/o/image/703339.jpg

只看該作者 · 發(fā)表于 2025-3-24 15:07:49

https://doi.org/10.1007/978-3-319-70197-4Anti - HER2 Therapy; Bisphosphonates; Endocrine Resistance; Non-invasive Breast Cancer; Sentinel Lymph N

只看該作者 · 發(fā)表于 2025-3-24 20:34:27

只看該作者 · 發(fā)表于 2025-3-25 03:15:12

		自動登錄	找回密碼
密碼			To register

關于派博傳思			派博傳思旗下網(wǎng)站			友情鏈接
派博傳思介紹	公司地理位置	論文服務流程	影響因子官網(wǎng)	吾愛論文網(wǎng)	大講堂	北京大學	Oxford Uni.	Harvard Uni.
發(fā)展歷史沿革	期刊點評	投稿經(jīng)驗總結	SCIENCEGARD	IMPACTFACTOR	派博系數(shù)	清華大學	Yale Uni.	Stanford Uni.
\|Archiver\|手機版\|小黑屋\| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-18 22:51
Copyright © 2001-2015 派博傳思京公網(wǎng)安備110108008328 版權所有 All rights reserved